{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:41:02Z","timestamp":1793036462743,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21fk0108135h0802"],"award-info":[{"award-number":["21fk0108135h0802"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22fk0108135h0803"],"award-info":[{"award-number":["22fk0108135h0803"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clinthera.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T01:15:07Z","timestamp":1669079707000},"page":"1604-1623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring"],"prefix":"10.1016","volume":"44","author":[{"given":"Yoshio","family":"Takesue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-7150","authenticated-orcid":false,"given":"Yuki","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-6507","authenticated-orcid":false,"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Mayumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1684","authenticated-orcid":false,"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0353-7933","authenticated-orcid":false,"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0869","authenticated-orcid":false,"given":"Yoshitsugu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-425X","authenticated-orcid":false,"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.10.005_bib0001","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Australasian Antifungal Guidelines Steering Committee. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"7","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/23744235.2017.1418531","article-title":"Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis","volume":"50","author":"Rosanova","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17652","article-title":"Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/myc.13293","article-title":"The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis","volume":"64","author":"Zhang","year":"2021","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.clinthera.2022.10.005_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"1","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0008","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/AAC.01900-12","article-title":"Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice","volume":"57","author":"Ohbuchi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0009","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/DDDT.S255427","article-title":"Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats","volume":"14","author":"Shen","year":"2020","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.clinthera.2022.10.005_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/pharmaceutics13050740","article-title":"Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats","volume":"13","author":"Lee","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0011","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3947\/ic.2013.45.4.406","article-title":"Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population","volume":"45","author":"Kim","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0012","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0013","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/AAC.03641-14","article-title":"Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients","volume":"58","author":"Vanstraelen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0017","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in inva-sive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0018","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0019","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0022","unstructured":"Minds Manual Developing Committee ed. Minds Manual for Guideline Development 2017. Tokyo: Japan Council for Quality Health Care, 2017 (in Japanese)."},{"key":"10.1016\/j.clinthera.2022.10.005_bib0023","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: A consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0024","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/jof7040306","article-title":"Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 \u00b5g\/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis","volume":"7","author":"Hanai","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0026","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0027","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0028","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/AAC.01430-12","article-title":"Pharmacodynamics of anidulafungin against clinical Aspergilus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0030","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0031","first-page":"991","article-title":"Pharmacokinetics and pharmacodynamics in the development of antifungal compounds","volume":"4","author":"Andes","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0032","article-title":"Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic\/Pharmacodynamic Model","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0033","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0034","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"International Society of Anti-Infective Pharmacology (ISAP), the PK\/PD study group of the European Society of Clinical Microbiology, Infectious Diseases (EPASG). From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.624639","article-title":"Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00493-21","article-title":"Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0038","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1128\/AAC.00970-16","article-title":"Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations","volume":"60","author":"Farkas","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0039","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","article-title":"A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions","volume":"59","author":"Li","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0040","article-title":"Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105061","article-title":"Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling","volume":"139","author":"Zhou","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0042","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","article-title":"A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children","volume":"53","author":"Zane","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02353-18","article-title":"Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study","volume":"63","author":"Hope","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0044","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/jac\/dkaa098","article-title":"Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package","volume":"75","author":"Chaudhri","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10928-016-9498-5","article-title":"Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole","volume":"44","author":"Bayard","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0046","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5649\/jjphcs.37.335","article-title":"Development of Software for Antimicrobial PK\/PD Simulation incorporating Montecarlo Simulation Based on Microsoft\u00ae Office Excel","volume":"37","author":"Oda","year":"2011","journal-title":"Jpn. J. Pharm. Health. Care. Sci."},{"key":"10.1016\/j.clinthera.2022.10.005_bib0047","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0048","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cpt.1012","article-title":"Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults","volume":"104","author":"Mangal","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0049","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijid.2020.02.041","article-title":"Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit","volume":"93","author":"Lin","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0050","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1128\/AAC.05010-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0051","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","article-title":"Genotyping of S-mephenytoin 4\u2032-hydroxylation in an extended Japanese population","volume":"60","author":"Kubota","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0052","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0053","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0054","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00228-016-2089-y","article-title":"Effect of Cytochrome P450 2C19 Polymorphisms on the Clinical Outcomes of Voriconazole: A Systematic Review and Meta-Analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0056","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1600-6143.2012.04042.x","article-title":"Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients","volume":"12","author":"Luong","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0057","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1186\/s12879-017-2913-8","article-title":"Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections","volume":"17","author":"Xing","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0058","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1439-0507.2012.02186.x","article-title":"Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience","volume":"55","author":"Racil","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0059","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/AAC.01316-08","article-title":"Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Trifilio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0061","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0062","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0063","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of Voriconazole Plasma Concentrations on Treatment Response in Critically Ill Patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0064","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FTD.0000000000000284","article-title":"Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care","volume":"38","author":"van Wanrooy","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/phar.1779","article-title":"Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit","volume":"36","author":"Wang","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0066","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/jcpt.12724","article-title":"A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis","volume":"43","author":"Wang","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0067","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1248\/bpb.b18-00164","article-title":"Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients With Severe Liver Cirrhosis (Child-Pugh Class C)","volume":"41","author":"Yamada","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0068","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1016\/j.ijid.2018.05.009","article-title":"Therapeutic Drug Monitoring and Safety of Voriconazole Therapy in Patients With Child\u2013Pugh Class B and C Cirrhosis: A Multicenter Study","volume":"72","author":"Wang","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0069","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0071","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0072","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal Drugs TDM: Trends and Update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0073","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/14787210.2017.1305886","article-title":"Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Marks","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0074","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0075","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0076","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0077","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0078","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1248\/yakushi.128.1811","article-title":"Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection","volume":"128","author":"Okuda","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0079","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4212\/cjhp.v62i6.845","article-title":"Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections","volume":"62","author":"Kuo","year":"2009","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1179\/1973947815Y.0000000057","article-title":"Therapeutic Drug Monitoring of Voriconazole in Japanese Patients: Analysis Based on Clinical Practice Data","volume":"28","author":"Matsumoto","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0081","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4414\/smw.2006.11547","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0082","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2022.10.005_bib0083","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0084","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/bcp.14267","article-title":"A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations","volume":"86","author":"Blanco Dorado","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0086","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/mmy\/myv099","article-title":"Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels","volume":"54","author":"Guinea","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0087","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0088","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0089","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00228-020-02841-z","article-title":"Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases","volume":"76","author":"Huang","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2022.10.005_bib0090","first-page":"5","article-title":"Effect of omeprazole on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Wood","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2022.10.005_bib0091","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0092","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2022.10.005_bib0093","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.clinthera.2022.10.005_bib0094","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0095","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106180","article-title":"Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices","volume":"56","author":"Imani","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0097","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"issue":"suppl_1","key":"10.1016\/j.clinthera.2022.10.005_bib0098","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0099","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.9.6.691","article-title":"Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China","volume":"9","author":"Chen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0100","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0101","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dku023","article-title":"Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"69","author":"Siopi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0103","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0104","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0105","first-page":"93","article-title":"Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis","volume":"47","author":"Hagiwara","year":"2009","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0106","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0107","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2013.05.025","article-title":"As-sociation of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity","volume":"424","author":"Suzuki","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0108","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0109","doi-asserted-by":"crossref","first-page":"e01211","DOI":"10.1128\/AAC.01211-17","article-title":"Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients","volume":"61","author":"Hashemizadeh","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5414\/CP203345","article-title":"Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin","volume":"57","author":"Hirata","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0111","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/FTD.0000000000000657","article-title":"Pharmacokinetic\/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients","volume":"41","author":"Perez-Pitarch","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijantimicag.2016.10.010","article-title":"Bioavailability of voriconazole in hospitalised patients","volume":"49","author":"Veringa","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0113","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jcpt.13352","article-title":"Influence of switching from intravenous to oral administration on serum voriconazole concentration","volume":"46","author":"Harada","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","article-title":"Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole","volume":"55","author":"Hohmann","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0115","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/cid\/ciw252","article-title":"Voriconazole Dosing in Obese Patients","volume":"63","author":"Eljaaly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0118","first-page":"1178","article-title":"Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy","volume":"72","author":"Richards","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2010.02.017","article-title":"Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis","volume":"36","author":"Burkhardt","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-6-6","article-title":"Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy","volume":"6","author":"von Mach","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/phar.2634","article-title":"Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction","volume":"42","author":"Lin","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0122","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12281-010-0015-9","article-title":"Antifungal dose adjustment in renal and hepatic dysfunction: Pharmacokinetic and pharmacodynamic considerations","volume":"4","author":"Cota","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0123","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/13693786.2012.694082","article-title":"Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies","volume":"51","author":"Lee","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0124","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2334-13-105","article-title":"Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events","volume":"13","author":"Chu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0126","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.eimc.2014.09.005","article-title":"Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital","volume":"33","author":"Cabral-Galeano","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0127","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/13693786.2011.630039","article-title":"Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients","volume":"50","author":"G\u00f3mez-L\u00f3pez","year":"2012","journal-title":"Med Mycol"},{"issue":"5","key":"10.1016\/j.clinthera.2022.10.005_bib0128","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2146\/ajhp150372","article-title":"Voriconazole concentration monitoring at an academic medical center","volume":"73","author":"Sebaaly","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0129","first-page":"62","article-title":"Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies","volume":"20","author":"Taghvaye-Masoumi","year":"2021","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5578\/flora.20229914","article-title":"Voriconazole therapeutic drug level monitoring: A university hospital experience","volume":"27","author":"Kara","year":"2022","journal-title":"FLORA"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0131","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1016\/j.xphs.2019.09.019","article-title":"Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis","volume":"108","author":"Ren","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0132","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-021-00994-3","article-title":"Clinical Pharmacokinetics of Triazoles in Pediatric Patients","volume":"60","author":"Bury","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0133","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","article-title":"Voriconazole: A Review of Population Pharmacokinetic Analyses","volume":"58","author":"Shi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0134","article-title":"Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization","volume":"12","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0135","article-title":"Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation","author":"Takahashi","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0136","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40268-021-00365-0","article-title":"Effects of Letermovir and\/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study","volume":"21","author":"Suetsugu","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0137","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00623-21","article-title":"CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation","volume":"65","author":"Takahashi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0138","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/phar.2474","article-title":"Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis","volume":"41","author":"Wang","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0139","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/bcp.14578","article-title":"Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study","volume":"87","author":"Tang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0140","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/FTD.0000000000000799","article-title":"Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization","volume":"42","author":"Chantharit","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0141","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/antibiotics9090574","article-title":"Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases","volume":"9","author":"Khan-Asa","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0142","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fphar.2020.00894","article-title":"Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0143","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.clinthera.2019.04.027","article-title":"Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies","volume":"41","author":"Liu","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0144","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s13318-019-00556-w","article-title":"Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation","volume":"44","author":"Chen","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/jcm8020227","article-title":"A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0146","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bcpt.13208","article-title":"Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach","volume":"125","author":"Tang","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0147","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0148","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/cap.2015.0137","article-title":"A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition","volume":"26","author":"Yu","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0149","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Li-Wan-Po","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","article-title":"Pharmacogenomics of triazole antifungal agents: Implications for safety, tolerability and efficacy","volume":"13","author":"Amsden","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0151","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2217\/pgs-2017-0173","article-title":"Pharmacogenetic of voriconazole antifungal agent in pediatric patients","volume":"19","author":"Allegra","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0152","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/mmy\/myaa008","article-title":"Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm","volume":"58","author":"Chan","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0153","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01245-19","article-title":"Impact of Triazole Therapeutic Drug Monitoring Availability and Timing","volume":"63","author":"McCreary","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0154","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Br\u00fcggemann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0155","first-page":"140","article-title":"Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic\/pharmacodynamic model","volume":"75","author":"Beredaki","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0156","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0157","first-page":"279","article-title":"Evaluation of voriconazole oral dosage in Japan","volume":"67","author":"Hamada","year":"2014","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0158","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.00251-13","article-title":"Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies","volume":"57","author":"Hoenigl","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2022.10.005_bib0159","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-010-0914-2","article-title":"Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients","volume":"67","author":"Berge","year":"2011","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:06:49Z","timestamp":1778634409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":159,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0149291822003538"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.10.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}